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of capecitabine administration cost, were derived from
DRG information issued by French Health Authorities.
For capecitabine, the administration cost (drug acquisi-
tion cost excluded) has been considered to be equal to 
the cost of an oncologist out-patient visit. RESULTS:
Efﬁcacy was assessed for 297 patients in the capecitabine
arm and for 299 patients in the FuFol arm based on 
an average follow-up of 165 days. The average costs for 
the management of metastatic colorectal cancer patients
with capecitabine and FuFol are respectively €4320 and
€10,311 (p < 0.001). Full administration costs (corre-
sponding to the drug acquisition cost plus the cost related
to the administration) are €3882 for capecitabine and
€9742 for FuFol (p < 0.001). Costs related to the treat-
ment of adverse events are €396 for capecitabine and
€537 for FuFol (p = 0.16). CONCLUSION: This cost
minimisation analysis shows that the use of capecitabine
results in very signiﬁcant savings on ﬁxed costs. Hospital
medical resources are becoming particularly scarce in
France. In this context, capecitabine is of high economic
interest for the treatment of metastatic colorectal cancer.
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OBJECTIVES: Evaluating the outcomes of prophylactic
care and estimating direct medical costs of CINV among
patients receiving emetogenic chemotherapy in Germany.
METHODS: Prospective, multi-center, cross-sectional,
cost-of-illness study (3 hospitals and 3 ofﬁce-based facil-
ities). Two hundred eight patients receiving level 4 or 5
emetogenic chemotherapy (Hesketh classiﬁcation) were
evaluable. Data were obtained from chart reviews and
patients’ diaries. We provide data on the subgroup of 137
patients who received chemotherapy at hospital (mean
age: 55 years; 61% male) and present costs from
providers’ perspective (hospital). RESULTS: Seventy-
three patients (53%) reported at least 1 episode of nausea
or vomiting, despite antiemetic prophylaxis. More
patients experienced delayed than acute CINV (50% vs.
20%) and more patients reported nausea than vomiting
(51% vs. 21%). Ninety percent and 71% of patients
received prophylactic antiemetic regimens for acute or
delayed CINV in compliance with ASCO (American
Society of Clinical Oncology) guidelines, respectively.
Twelve percent of patients receiving prophylaxis for
delayed symptoms according to ASCO guidelines experi-
enced delayed vomiting in contrast to 34% of the group
whose treatment did not follow the guidelines (p < 0.05).
One patient was rehospitalized due to CINV; 12 patients
received rescue medication at hospital. Mean direct
medical costs for antiemetic prophylaxis per patient and
treatment cycle were €34 (SD 11). Mean direct costs due
to CINV per patient and cycle were €15 (SD 81). Staff
time and material consumption associated with manag-
ing episodes of CINV was the main cost driver (92%).
Rescue medication (administered inside hospital) is
responsible for 8% of those costs. CONCLUSIONS: In
the hospital setting we found considerable room for
improvement in processes and outcomes of care regard-
ing guideline adherence for antiemetic prophylaxis of
delayed CINV. Aside from its clinical consequences,
CINV has an additional economic impact in oncology
centers. Improved CINV prophylaxis may potentially
offset some of costs of CINV treatment.
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OBJECTIVE: To estimate costs associated with manage-
ment of chemotherapy-induced toxicity with pemetrexed
compared with docetaxel as second-line chemotherapy
for advanced non-small cell lung cancer (NSCLC).
METHODS: Resource utilization data were analysed
from a multinational phase III randomised trial compar-
ing pemetrexed (ALIMTA®) with docetaxel (N = 571).
Costs included in this initial analysis were hospitalisa-
tions, transfusions, erythropoietin, granulocyte colony-
stimulating factors (GCSFs) and parenteral antibiotics.
Unit costs were sourced from UK National Health Service
(NHS) case mix data (2002) and national drug prices.
RESULTS: Efﬁcacy was shown to be similar with median
survival times of approximately 8 months for both arms,
although toxicity-related events and need for medical
management were lower for pemetrexed. CTC grade 3/4
neutropenia and neutropenic fever were signiﬁcantly
higher for docetaxel (40% vs. 5%, 13% vs. 2%, respec-
tively). Most other grade 3/4 toxicities, including
nausea/vomiting, diarrhoea, thrombocytopenia and
anaemia, occurred at low rates (£5%) and were similar
between treatment arms. The most common reasons for
drug-related hospitalisation for both arms were febrile
neutropenia and neutropenia (4 admissions on the peme-
trexed arm [£4730] vs. 42 on the docetaxel arm
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[£48,554]). Admissions for other drug-related toxicities
were lower for pemetrexed (17 admissions [£15,020]) vs.
docetaxel (31 admissions [£27,091]). Average cost of
these hospitalisations was £75 and £274 for pemetrexed
and docetaxel, respectively. More patients on the peme-
trexed arm received red blood cell transfusions (17% vs.
12%), however, more patients on the docetaxel arm
received erythropoietin (10% vs. 7%). Patients on the
pemetrexed arm received fewer courses of parenteral
antibiotics and GCSF and required fewer hospital admis-
sions and days. Total average costs were £159 and £484
for the pemetrexed and docetaxel arms, respectively.
CONCLUSIONS: In the second-line treatment of
NSCLC, pemetrexed offers similar efﬁcacy to docetaxel
but better tolerability. This results in less expensive man-
agement of chemotherapy-related adverse events, primar-
ily through reduced hospitalisation.
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OBJECTIVE: Estimate and compare resource use and
costs associated with RBC transfusions in the manage-
ment of anaemia among cancer patients treated with
chemotherapy in one French and one Austrian setting.
METHOD: The same ABC study protocol was used:
structured interviews were held with key personnel at the
oncology ward to obtain a detailed overview of the activ-
ities, frequencies, resource use and related links to other
hospital departments when administering RBC transfu-
sions. Sequential tasks were grouped into activity blocks
with clear start- and end-points. A trained centre nurse
measured the time devoted to each activity block with a
stopwatch. The time devoted to isolated or less frequent
activities was estimated from interviews. Unit costs for
personnel time, supplies, laboratory tests, waste manage-
ment and overhead costs were collected in each centre.
RESULTS: Seven transfusions were observed in the
French and eight in the Austrian setting. The average
duration per transfusion, including all the observed and
non-observed activities performed by the different health
care professionals (physician, blood bank physician,
nurse, auxiliary nurse, receptionist and lab technician)
was 3 hours 15min (min: 1h50; max: 4h50) in the Aus-
trian setting and 4 hours 31min (min: 2h35; max: 6h39)
in the French setting. A different organisational structure
in the blood transfusion centres explains the time differ-
ence observed. The average cost per transfusion was €361
(min: €315; max: €411) in Austria and €396 (min: €224;
max: €452) in France. Personnel costs in Austria were
higher than in France, but the ofﬁcial listed hospital price
for 1 RBC blood pack in Austria was considerably lower
(€115 versus €166). CONCLUSION: Time involved in
one RBC transfusion among anaemic cancer patients 
may differ substantially between centres due to different
organisational structures. Comparing the average cost per
transfusion between countries may not reﬂect these dif-
ferences when important unit cost variations between
European countries exist.
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OBJECTIVES: Britain has one of the highest breast
cancer rates in the world with around 36,000 women
newly diagnosed each year. With improving survival rates
on average 90% of women are still alive 5 years later. The
ATAC trial (median follow-up 47.2 months) conﬁrmed
that anastrozole resulted in a 18% reduction in the risk
of disease recurrence relative to tamoxifen in this popu-
lation. Our study aimed to identify the budget impact of
anastrozole compared to tamoxifen in postmenopausal
women with early breast cancer based on alternative sce-
narios of uptake over three years from the NHS perspec-
tive. METHODS: The budget impact model was based
on a modelled cost-effectiveness analysis of the ATAC
trial data. Published UK data was used to estimate the
treatment eligible population each year. Different scenar-
ios about uptake were deﬁned and the net budgetary
effects calculated. Costs were discounted at 6% annu-
ally. Probabilistic sensitivity analysis was undertaken.
RESULTS: For a total number of around 13,200 HR +
EBC patients each year the cost of drug treatment with
tamoxifen is estimated to be £64.6 million. Under the
projected likely scenario of uptake reaching 35% by
2006, the net present value of the incremental drug costs
with anastrozole will amount to £18.4 million. This is
offset by £3.4 million by avoiding breast cancer recur-
rences, AEs and follow-up costs. The model is sensitive
to the rate of uptake. CONCLUSIONS: The budgetary
impact of anastrozole for all available patients is less 
than 7% of the annual amount spent on breast cancer in
the UK. If the subpopulation with high risk of throm-
boembolic and cardiovascular disease were included the
impact will be lower. Other technologies with similar
budget impact have been approved but NICE. Accompa-
nying the cost-effectiveness analysis the budget impact is
going to be an important input into the forthcoming
policy decision about the adoption of anastrozole in EBC
patients.
